Q2 Earnings Forecast for RYTM Issued By HC Wainwright

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Research analysts at HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for shares of Rhythm Pharmaceuticals in a report issued on Monday, March 24th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.40) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q3 2026 earnings at ($0.31) EPS and Q4 2026 earnings at ($0.18) EPS.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%. The company had revenue of $41.83 million during the quarter, compared to analysts’ expectations of $38.48 million.

Several other equities analysts also recently commented on RYTM. Oppenheimer assumed coverage on Rhythm Pharmaceuticals in a research report on Friday, December 20th. They issued an “outperform” rating and a $76.00 price objective on the stock. The Goldman Sachs Group boosted their price target on Rhythm Pharmaceuticals from $59.00 to $66.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. Jefferies Financial Group initiated coverage on Rhythm Pharmaceuticals in a research note on Thursday, January 2nd. They issued a “buy” rating and a $80.00 price target for the company. Canaccord Genuity Group lifted their price objective on shares of Rhythm Pharmaceuticals from $80.00 to $81.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. Finally, Needham & Company LLC boosted their target price on shares of Rhythm Pharmaceuticals from $64.00 to $66.00 and gave the stock a “buy” rating in a report on Tuesday, March 18th. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $69.46.

Rhythm Pharmaceuticals Trading Up 3.2 %

Rhythm Pharmaceuticals stock opened at $53.72 on Tuesday. Rhythm Pharmaceuticals has a 12-month low of $35.17 and a 12-month high of $68.58. The firm has a market capitalization of $3.40 billion, a price-to-earnings ratio of -12.41 and a beta of 2.30. The firm has a 50 day moving average of $55.28 and a 200 day moving average of $54.99.

Insider Buying and Selling

In other Rhythm Pharmaceuticals news, CAO Christopher Paul German sold 635 shares of the business’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $57.22, for a total value of $36,334.70. Following the completion of the transaction, the chief accounting officer now directly owns 2,070 shares in the company, valued at approximately $118,445.40. The trade was a 23.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Joseph Shulman sold 1,281 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $59.43, for a total transaction of $76,129.83. Following the completion of the sale, the insider now owns 2,657 shares of the company’s stock, valued at $157,905.51. This trade represents a 32.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 108,131 shares of company stock valued at $5,781,098 over the last 90 days. Corporate insiders own 5.60% of the company’s stock.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. FMR LLC boosted its stake in Rhythm Pharmaceuticals by 79.7% during the 3rd quarter. FMR LLC now owns 50,295 shares of the company’s stock worth $2,635,000 after purchasing an additional 22,306 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Rhythm Pharmaceuticals by 307.1% during the third quarter. BNP Paribas Financial Markets now owns 14,425 shares of the company’s stock worth $756,000 after purchasing an additional 10,882 shares in the last quarter. Principal Financial Group Inc. lifted its stake in Rhythm Pharmaceuticals by 241.9% during the 3rd quarter. Principal Financial Group Inc. now owns 32,586 shares of the company’s stock worth $1,707,000 after acquiring an additional 23,054 shares in the last quarter. Intech Investment Management LLC purchased a new position in shares of Rhythm Pharmaceuticals in the third quarter valued at approximately $649,000. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Rhythm Pharmaceuticals by 1.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 433,866 shares of the company’s stock worth $22,730,000 after acquiring an additional 5,908 shares in the last quarter.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.